Krishna Institute of Medical Sciences Limited — PPTs, 06-02-2025: Investor Presentation

**Financial Highlights:**

Q3 FY25 consolidated gross revenue reached ₹790 Cr, growing by 29.7% year-on-year. EBITDA stood at ₹205 Cr, reflecting a 36.4% increase versus Q3 FY24, although it declined 8.1% quarter-on-quarter. The EBITDA margin enhanced to 25.9%, compared to 24.7% in the same quarter last year. PAT for Q3 was ₹93 Cr, an increase from ₹77 Cr in Q3 FY24, but down from ₹121 Cr in Q2 FY25. Consolidated EPS for the nine months is ₹7.1, marking a 15.6% growth.

**Strategic Initiatives and Growth Drivers:**

KIMS continues its expansion with multiple projects in Bengaluru, Thane, Srikakulam, Ongole, and Anantapur, adding a significant number of beds and new specialties, with capex ranging from ₹40-525 Cr. The company aims for operational launches starting Q4 FY25 through Q1 FY27.

**Business Developments:**

KIMS is operationalizing advanced medical technologies, including da Vinci Robotic Systems across four units, enhancing its surgical capabilities. The successful acquisition of the MRI-guided focused ultrasound system offers non-invasive treatments for tremors, demonstrating KIMS's commitment to cutting-edge patient care.

**Market Position and Competitive Advantage:**

KIMS holds a significant position across multiple states with a diverse specialty mix, including Cardiology and Neurology, and notable leadership in organ transplantation and joint replacement programs. This competitive edge is strengthened by its strong financial growth trajectory and comprehensive service offerings.

**Investor Implications:**

The robust revenue and EBITDA growth indicate a positive outlook for KIMS, backed by strategic expansions and operational efficiencies. Investors should monitor ongoing projects and technological advancements, which could enhance market position and drive future profitability.